ASP 4396
Alternative Names: ASP-4396Latest Information Update: 22 Jun 2024
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06364696)
- 15 Apr 2024 Preclinical trials in Solid tumours in Japan (IV) before April 2024 (NCT06364696)
- 15 Apr 2024 Astellas Pharma plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in April 2024 (IV) (NCT06364696)